Bevyxxa Will Join Other Anticoagulant Meds on the Market

March 2018

You may see some patients get Bevyxxa (beh-VYKE-sah, betrixaban), a new direct oral anticoagulant (DOAC).

It's not used the same way as other DOACs...Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis (apixaban), or Savaysa (edoxaban).

Bevyxxa is only approved to PREVENT blood clots in the leg or lungs in certain hospitalized adults with multiple risk factors...such as reduced mobility plus older age and heart failure.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Safety Watch for Common Causes of Confusion on Med Labels
Hospital Practice Boost Your Accuracy When Checking a Colleague's Work
New Generics Stay Alert for Differences Among Daptomycin Products
Privacy & HIPAA Think About HIPAA Implications When Handling Patient Info
Nausea & Vomiting Cinvanti and Varubi Are New IV Antiemetics for Chemo-Induced Nausea and Vomiting
Shortages Use Appropriate Alternatives When Sterile Water Supplies Run Dry
Substance Use Disorder Know Which Meds Are Used to Treat Severe Alcohol Withdrawal
Anticoagulants Bevyxxa Will Join Other Anticoagulant Meds on the Market
Substance Use Disorder Include Sublocade for Opioid Use Disorder on Med Histories
Poisoning You May Be Surprised by Some Meds That Are Misused

Bevyxxa Will Join Other Anticoagulant Meds on the Market

Practical advice for a better career, with unlimited access to CE

Table of Contents